169 related articles for article (PubMed ID: 35900489)
1. Prevalence of precursor lesions (P53 signature, SCOUT, STIL, STIC) in fallopian tubes resected for non-neoplastic causes.
Tewari S; Misra V; Kumar V; Mishra RR; Yadav K; Paridhi ; Sangma H
Indian J Pathol Microbiol; 2022; 65(3):610-616. PubMed ID: 35900489
[TBL] [Abstract][Full Text] [Related]
2. Secretory cell outgrowths, p53 signatures, and serous tubal intraepithelial carcinoma in the fallopian tubes of patients with sporadic pelvic serous carcinoma.
Mittal N; Srinivasan R; Gupta N; Rajwanshi A; Nijhawan R; Gautam U; Sood S; Dhaliwal L
Indian J Pathol Microbiol; 2016; 59(4):481-488. PubMed ID: 27721278
[TBL] [Abstract][Full Text] [Related]
3. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
Wen J; Shi JL; Shen DH; Chen YX; Song QJ
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
[TBL] [Abstract][Full Text] [Related]
4. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
5. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
Mahe E; Tang S; Deb P; Sur M; Lytwyn A; Daya D
Int J Gynecol Pathol; 2013 Jul; 32(4):353-7. PubMed ID: 23722507
[TBL] [Abstract][Full Text] [Related]
6. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas.
Horn LC; Kafkova S; Leonhardt K; Kellner C; Einenkel J
Int J Gynecol Pathol; 2013 Jul; 32(4):339-44. PubMed ID: 23722505
[TBL] [Abstract][Full Text] [Related]
7. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
8. The association of serous tubal intraepithelial carcinoma with gynecologic pathologies and its role in pelvic serous cancer.
Koç N; Ayas S; Uygur L
Gynecol Oncol; 2014 Sep; 134(3):486-91. PubMed ID: 25038287
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Expression Status of p53, CD44v9, and Ki-67 in a Series of Fallopian Tube Lesions of High-grade Serous Carcinoma.
Sugimoto S; Uchiyama T; Kawahara N; Ohbayashi C; Kobayashi H
Int J Gynecol Pathol; 2021 Sep; 40(5):419-426. PubMed ID: 34397764
[TBL] [Abstract][Full Text] [Related]
10. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
[TBL] [Abstract][Full Text] [Related]
11. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
12. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL
J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554
[TBL] [Abstract][Full Text] [Related]
14. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
Roh MH; Kindelberger D; Crum CP
Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565
[TBL] [Abstract][Full Text] [Related]
15. Serous tubal intra-epithelial carcinoma: what do we really know at this point?
Vang R; Shih IM
Histopathology; 2022 Nov; 81(5):542-555. PubMed ID: 35859323
[TBL] [Abstract][Full Text] [Related]
16. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
Cass I; Walts AE; Barbuto D; Lester J; Karlan B
Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
[TBL] [Abstract][Full Text] [Related]
17. [Fallopian tube: the dark face of pelvic carcinogenesis].
Watkin E; Devouassoux-Shisheboran M
Ann Pathol; 2011 Oct; 31(5):345-52. PubMed ID: 21982240
[TBL] [Abstract][Full Text] [Related]
18. [Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas].
Asaturova AV; Ezhova LS; Faizullina NM; Adamyan LV; Khabas GN; Sannikova MV
Arkh Patol; 2017; 79(3):10-18. PubMed ID: 28631711
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the fallopian tubes after neoadjuvant chemotherapy: persistence of serous tubal intraepithelial carcinoma.
Colón E; Carlson JW
Int J Gynecol Pathol; 2014 Sep; 33(5):463-9. PubMed ID: 25083961
[TBL] [Abstract][Full Text] [Related]
20. [The morphological and immunohistochemical characteristics of changes in the fallopian tube mucosa in ovarian epithelial tumors].
Asaturova AV; Ezhova LS; Faizullina NM; Sannikova MV; Khabas GN
Arkh Patol; 2016; 78(2):3-9. PubMed ID: 27070769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
